

Attorney Docket No.: DEX-0184
Inventors: Roberto A. Macina
Serial No.: 09/806,311
Filing Date: July 18, 2001
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for ~~diagnosing~~
~~detecting~~ the presence of a ~~gastrointestinal~~ cancer of the
~~stomach or small intestine~~ in a patient comprising:

(a) measuring levels of CC2 in cells, tissues or bodily fluids in a patient; and

(b) comparing the measured levels of CC2 with levels of CC2 in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CC2 in said patient versus normal human control is associated with the presence of a ~~gastrointestinal~~ cancer of the stomach or small intestine.

Claim 2 (original): A method of diagnosing metastases of a gastrointestinal cancer in a patient comprising:

(a) identifying a patient having a gastrointestinal cancer that is not known to have metastasized;

(b) measuring CC2 levels in a sample of cells, tissues, or bodily fluid from said patient; and

(c) comparing the measured CC2 levels with levels of CC2 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CC2 levels in the patient versus the

BEST AVAILABLE COPY

Attorney Docket No.: DEX-0184
Inventors: Roberto A. Macina
Serial No.: 09/806,311
Filing Date: July 18, 2001
Page 3

normal human control is associated with a cancer which has metastasized.

Claim 3 (original): A method of staging a gastrointestinal cancer in a patient having a gastrointestinal cancer comprising:

- (a) identifying a patient having a gastrointestinal cancer;
- (b) measuring CC2 levels in a sample of cells, tissue, or bodily fluid from said patient; and

(c) comparing measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in measured CC2 levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the measured CC2 levels is associated with a cancer which is regressing or in remission.

Claim 4 (original): A method of monitoring a gastrointestinal cancer in a patient for the onset of metastasis comprising:

- (a) identifying a patient having a gastrointestinal cancer that is not known to have metastasized;
- (b) periodically measuring levels of CC2 in samples of cells, tissues, or bodily fluid from said patient; and
- (c) comparing the periodically measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal

BEST AVAILABLE COPY

Attorney Docket No.: DEX-0184
Inventors: Roberto A. Macina
Serial No.: 09/806,311
Filing Date: July 18, 2001
Page 4

human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

Claim 5 (original): A method of monitoring a change in stage of a gastrointestinal cancer in a patient comprising:

- (a) identifying a patient having a gastrointestinal cancer;
- (b) periodically measuring levels of CC2 in cells, tissues, or bodily fluid from said patient; and
- (c) comparing the periodically measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

Claim 6 (original): The method of claim 1, 2, 3, 4 or 5 wherein the CC2 comprises SEQ ID NO:1 or SEQ ID NO:2.

Claim 7 (original): An antibody which specifically binds CC2.

Claim 8 (original): A method of imaging a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

BEST AVAILABLE COPY

Attorney Docket No.: DEX-0184
Inventors: Roberto A. Macina
Serial No.: 09/806,311
Filing Date: July 18, 2001
Page 5

Claim 9 (original): The method of claim 8 wherein said antibody is labeled with paramagnetic ions or a radioisotope.

Claim 10 (original): A method of treating a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

Claim 11 (original): The method of claim 10 wherein the antibody is conjugated to a cytotoxic agent.

BEST AVAILABLE COPY